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Indomethacinmmediated reversal of multidrug resistance
and drug efflux in human and murine cell lines
overexpressing MRP, but not P-glycoprotein
MP Draper, RL Martell and SB Levy
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Summary Decreased accumulation of the fluorescent dye BCECF [2', 7'-bis-(2-carboxyethyl)-5-(6)- carboxyfluorescein] characterized murine
and human multidrug-resistant cell lines overexpressing the multidrug resistance protein (MRP). Indomethacin (10 gM), a known cyclo-
oxygenase and glutathione-S-transferase inhibitor as well as a modulator of anion transport, increased accumulation and blocked efflux of
BCECF in MRP-expressing murine and human cells. The drug did not affect P-glycoprotein (P-gp)-mediated export of rhodamine 123. The
indomethacin effect on BCECF efflux was not reversed by the addition of exogenous prostaglandins, suggesting that the drug acts by a
mechanism other than decreasing prostaglandin synthesis. Indomethacin also increased multidrug susceptibility of both murine and human
cell lines overexpressing MRP, but not those displaying P-gp-associated resistance. In addition, indomethacin modulated the decreased
vincristine accumulation in cells expressing MRP, but not in those expressing P-gp. These data suggest that indomethacin is aspecific inhibitor
of MRP, possibly functioning by inhibition of glutathione-S-transferase or, alternatively, by direct competition with the drug at the transport site.
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Multidrug resistance in mammalian cells has been associated with
altereddrugtransport. Activeefflux oralteredintracellular sequestra-
tion has been attributed to membrane-associated P-glycoprotein (P-
gp) or the multidrug resistance protein (MRP) (Inaba et al, 1979;
Zamon et al, 1994). We have previously demonstrated that murine
and human cell lines that overexpressed MRP also showed altered
accumulation and increased efflux of the free acid form of the
fluorescent dye BCECF (Draper et al, 1996). BCECF is loaded into
the cells as the membrane-permeable acetoxymethyl (AM) ester,
BCECF-AM. This lipophilic ester derivative can cross cell
membranes, entering the cytoplasm and various organelles, where
the AM ester is hydrolysed by intracellular esterases to release
BCECFfree acid, which is normally retained by thecell. Weusedthe
altered BCECF accumulation phenotype ofcell lines overexpressing
MRPto look fordrugs thatcouldmodulate MRPfunction. Oneofthe
drugs examined first was indomethacin as it has previously been
reported to modulate efflux of BCECF from cultured epithelial cell
monolayers, although the mechanism is unknown (Collington et al.,
1992). We report here on the ability of indomethacin, a member of
the non-steroidal family of anti-inflammatory drugs (NSAID), to
specifically modulate MRP-mediated resistance.
MATERIALS AND METHODS
Cell culture
The murine erythroleukaemia (MEL) cell line, PC4, and its drug-
resistant derivatives were cultured in basal medium Eagle (BME)
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containing 10% fetal bovine serum as previously described
(Slapak et al, 1994). Human HL60 and HL60 derivative cell lines
(kindly provided by M. Center, Kansas State University) were
grown in RPMI media containing 10% fetal bovine serum, 5 mM
glutamine, 100 units ml-' penicillin and 100jg ml-' streptomycin.
All cultures were incubated in a Revco Ultima incubator set at 5%
carbon dioxide.
Fluorescence measurements
Cells were washed once in phosphate-buffered saline (PBS)
containing 1 mg ml-' glucose (PBS-glucose) and resuspended in
either minimal essential medium (MEM), equilibrated in a 5%
carbon dioxide atmosphere lacking phenol red or PBS-glucose, as
indicated, at a concentration of2.5 x 106 cells ml-'. The dye 2', 7'-
bis-(2-carboxyethyl) -5-(6)-carboxyfluorescein acetoxymethylester
(BCECF-AM) (MolecularProbes, Eugene, OR, USA) was added at
aconcentration of2gM, and the cells were incubated at 37°C for 15
min. Cells were then pelleted by centrifugation, the supematant
fluid removed and the cell pellet placed on ice. Cells, resuspended
in fresh MEM or PBS-glucose at a concentration of2.5 x 106 cells
ml-', were analysed on a Hitachi F-2000 Fluorescence spectropho-
tometer (Tokyo, Japan) at excitation wavelengths 439 nm and 505
nm and the emission measurements at 535 nm. Experiments
designed to examine the accumulation of 2 giM rhodamine were
conducted in a similar manner except that an excitation wavelength
of500 nm and an emission wavelength of534 nm were used.
Analysis of drug efflux
Equal numbers of cells were incubated with BCECF-AM as
described above except that 10 giM indomethacin was added to
normalize the dye loading among the cell lines. Cells were then
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Figure 1 Effect of indomethacin on BCECF accumulation in human and murine leukaemia cell lines overexpressing MRP and/or P-gp. Data are the mean ± s.d.
of at least three experiments reported as percentage accumulation of BCECF compared with the appropriate wild type (WT) control (without indomethacin).
Accumulation of BCECF was assayed by fluorescence measurements, performed as described in Materials and methods. + and - symbols indicate the
presence or absence of indomethacin (10 gM). (A) Murine cell lines: PC4-WT (WT), PC-V40 (V40) and PC-V160 (V160). (B) Human cell lines: HL60-WT (WT),
HL60/ADR (ADR) and HL6ONinc (Vinc)
washed in PBS, collected by centrifugation and resuspended in
PBS-glucose with or without 10 gM indomethacin and placed in a
shaking water bath at 37°C. Samples, taken at the indicated time
points, were centrifuged to collect the cells and kept on ice before
assaying by fluorescence spectroscopy for the amount of dye
retained, as described above.
Drug susceptibility studies
Sensitivity of each cell line to the chemotherapeutic agents,
vincristine, doxorubicin or etoposide, was determined using the
48-h MTT colorimetric assay (Mosmann, 1983; Slapak et al,
1990). Briefly, 1 ml of2 x 104 cells, with or without indomethacin
(10 gM), were seeded into a 24-well plate containing increasing
concentrations of the chemotherapeutic agent. After a 48-h incu-
bation, cells were assayed for viability by the MTT assay. The IC50
(dose of drug which reduced the final absorbance to 50% of
control) was read from the dose-response curves.
Vincristine steady-state accumulation studies
Vincristine (VCR) accumulation was assayed in 106 cells ml-' after
a 60 min incubation at 37°C in PBS-glucose (1 mg ml-') using 25
nM [G-3H]vincristine sulphate (6.6-8.6 Ci mmol-', Amersham,
Arlington Heights, IL, USA) in the absence or presence of
indomethacin (10 gM). Cell-associated radioactivity was deter-
mined after centrifugation of samples (2 x 105 cells) through sili-
cone oil in microfuges tubes previously prepared with 20 ul of
formic acid overlaid with 200 gl of silicone oil (density =
1.035-1.046, Nye Lubricants, New Bedford, MA USA). After
freezing the tubes, the tips were severed (containing the frozen
formic acid/cell pellet) and the cell-associated radioactivity was
determined by scintillation counting.
RESULTS
Effect of indomethacin on BCECF-AM accumulation in
murine or human cells expressing MRP and/or P-gp
We have previously shown that multidrug-resistant human and
murine cell lines expressing the MRP have a decreased accumula-
tion of the fluorescent dye BCECF, reflecting increased dye
efflux (Draper et al, 1996). We examined the effect of various
compounds on BCECF accumulation in MRP-overexpressing
murine (PC4) (Slapak et al, 1994) and human (HL60)
(Krishnamachary et al, 1994) leukaemia cell lines. One such
compound, indomethacin (10 gM), caused a dramatic increase in
the accumulation of BCECF in both the murine (PC-V40) and the
human (HL60/ADR) MRP-expressing cell lines, normalizing drug
accumulation to wild type levels (Figure 1). The murine PC4-WT
and PC-V160 (overexpressing both P-gp and MRP) (Slapak et al,
1994) also showed an increase in BCECF accumulation, however,
neither HL60WT nor HL60/Vinc (a P-gp-overexpressing cell line)
(McGrath et al, 1989) showed an increase in BCECF accumula-
tion. This pattern suggested activity against cells expressing MRP.
The indomethacin-mediated increase in BCECF accumulation
in PC4-WT could be the result ofthe low levels ofMRP expressed
in these cells (Slapak et al, 1994). Indomethacin appeared to have
a greater effect on the MRP-overexpressing murine cells than
on the human cell lines. Use of indomethacin at concentrations
less than 1 ,UM caused little change in BCECF accumulation (data
not shown).
A 1-h incubation of cells (PC4-WT, PC4-V40 and PC4-V160)
with 10 gM indomethacin did not detectably alter the intracellular
glutathione (GSH) content (e.g. PC4-V40; control = 2.5 + 0.15
nmol 10- cells, indomethacin = 2.4 ± 0.25 nmol 10- cells).
Indomethacin is a potent inhibitor of cyclo-oxygenase activity.
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Figure 2 Effect of indomethacin on the efflux of BCECF. Efflux experiments
were performed as described in Materials and methods. Data are the mean
of three experiments and are expressed as a percentage of BCECF present
at time zero. By paired t-tests, the values for PC-V40 (+) indomethacin
versus (-) indomethacin at the 20-min time point were significant at P < 0.05.
+ and - indicate the presence or absence of indomethacin (10gM)
However, inhibition of cyclo-oxygenase did not appear to be the
mechanism behind the modulation ofBCECF accumulation as the
addition ofexogenous prostaglandins (0.1 ,IM PGE1 or PGE2) did
not detectably modify the altered BCECF accumulation in the
MRP-overexpressing cell lines, nor did they ameliorate the effect
of 10 gM indomethacin on BCECF accumulation in these cell lines
(data not shown).
Effect of indomethacin on efflux of BCECF by
multidrug-resistant murine cell lines
We examined whether the indomethacin-mediated increased accu-
mulation of BCECF was due to inhibition of dye efflux. Murine
cell lines were loaded with BCECF in the presence of 10 JM
indomethacin which normalized the dye loading among the cell










Figure 3 Rhodamine accumulation in murine (A) and human (B) cell lines
expressing MRP and/or P-gp. Accumulation of rhodamine was performed as
described in Materials and methods. Data are the mean ± s.d. of at least
three experiments. Cells were incubated without (-) or with (+) 10gM
indomethacin. Results are presented as percentage accumulation compared
with the appropriate wild type control in the absence of indomethacin. (A)
PC-WT (WT), PC-V40 (V40) and PC-V160 (V160); (B) HL60-WT (WT),
HL60/ADR (ADR) and HL6ONinc (Vinc)
extracellular BCECF-AM derivative or indomethacin and allowed
to incubate in BCECF-AM-free PBS-glucose at 370C in the pres-
ence or absence of indomethacin (10 gM). At various times,
samples were taken to determine the dye levels in the cells. The
presence ofindomethacin inhibited the efflux ofdye from the PC-
V40 cell line (Figure 2A). A small effect was noted in PC-V160
which overexpresses MRP as well as P-gp (Slapak et al, 1994).
These findings indicate that the increased accumulation ofBCECF
in cells incubated with indomethacin likely occurred via inhibition
ofefflux ofthe free-acid form ofBCECF.
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Table 1 Effect of indomethacin on drug susceptibility in murine and human cell lines
IC a scoa
Cell line Doxb VCRb
(ABC transporter) (fold resistance)c (fold resistance)c
Control +Indomethacin Control +Indomethacin
Murine
PC4-WT ND ND 2.5 ± 0.26 1.6 ± 0.35
(1) (0.64)
PC-V40 (MRP) ND ND 167± 17 31 ±9.5
(67) (12)
PC-Vl60 (MRP and P-gp) ND ND 330 + 60 350 ± 87
(132) (140)
PC4-80 (P-gp)d ND ND 78 ± 7 102 ± 39
(31) (41)
Human
HL60WT 43 ± 5.7 36 ± 5.7 1.03 ± 0.03 0.63 ± 0.08
(1) (.93) (1) (.61)
HL60/ADR (MRP) 4333 ±570 1000 ± 115 22+ 2 2.8± 0.7
(100) (25) (21) (2.7)
HL60Ninc (P-gp) ND ND 900 ± 60 950 ± 70
(873) (922)
alC50 (ng ml-') as determined by 48-h MTT assay. Data are the mean ± s.d. of three experiments. bDOX, doxorubicin; VCR, vincristine. cFold resistance
compared with wild type cells assayed without indomethacin. Fold resistance was calculated by dividing the mean IC50 value by that for the parental cells (PC4-
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Figure 4 Effect of indomethacin on vincristine accumulation in murine
erythroleukaemia cell lines overexpressing the MRP and/or P-gp. Data are
the mean ± s.d. of at least three experiments reported as fmol of drug 10-
cells. Accumulation of vincristine was assayed as described in Materials and
methods. + and - symbols indicate the presence or absence of indomethacin
(10 gM). Murine cell lines: PC4-WT (WT), PC-V40 (MRP overexpressing)
(V40), PC-Vl60 (MRP and P-gp overexpressing) (Vi 60) and PC4-80 (P-gp
overexpressing) (A80)
Effect of indomethacin on rhodamine transport
Rhodamine 123 has previously been shown to be a substrate for
transport by P-gp (Tapiero et al, 1984). We examined the ability of
cells expressing MRP or P-gp to accumulate rhodamine. As
expected, the P-gp-expressing murine (PC-V160) and human
(HL6O/Vinc) cell lines showed a markedly decreased accumula-
tion of rhodamine (Figure 3A and B). In contrast, the MRP-
expressing lines (PC-V40 and HL60/ADR) showed no altered
rhodamine accumulation compared with parental cells and, in fact,
exhibited a slight increase in drug accumulation. This is in accord
with previous results showing no altered accumulation of
rhodamine, within the first 30 min ofuptake, between parental and
MRP-expressing cell lines (Twentyman et al, 1994). We then
examined the effect of indomethacin on rhodamine accumulation.
Indomethacin did not affect the accumulation of rhodamine by
either MRP- or the P-gp-overexpressing cell lines compared with
controls (Figure 3).
Effect of indomethacin on drug susceptibility of murine
and human cell lines
We examined the ability of indomethacin to function as a
chemosensitizing agent. As determined by the MTT assay, theICIO
for indomethacin was 50gM for the wild-type and resistant murine
cell lines and 20 gM for all the human cell lines. At a concentration
of 10 gM, no toxicity was noted. In a 48-h MTT cell viability
assay, 10 gM indomethacin reversed MRP-mediated vincristine
resistance in both the murine and human cell lines (Table 1). As
little doxorubicin resistance is expressed by the murine PC-V40,
we examined the effect ofindomethacin on doxorubicin resistance
in the HL60/ADR cell line which overexpresses MRP and was
originally established in doxorubicin. Against HL60/ADR
indomethacin produced a dramatic chemosensitization to doxoru-
bicin (Table 1). Indomethacin had no effect on P-gp-mediated
vincristine resistance, further suggesting its specificity as a
MRP modulator (Table 1). Ofnote, indomethacin had no effect on
PC-V160 (expressing both MRP and P-gp) which is in accord
with its previously noted P-gp-dominant phenotype (Figure 3)
(Draper et al, 1996).
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Effect of indomethacin on vincristine accumulation
We evaluated the effect of indomethacin on a 60-min vincristine
accumulation in the murine PC4-WT, PC-V40 (MRP expressing),
PC-V160 (MRP and P-gp expressing) and the doxorubicin-
selected P-gp-expressing PC4-80 cell lines. Indomethacin modu-
lated the altered vincristine accumulation only in the PC-V40
(MRP expressing) cell line (Figure 4). Slight increases in
vincristine accumulation were noted in the other cell lines, consis-
tent with the BCECF accumulation data (Figure 1). This slight
increase could be due to the effect of indomethacin on the low
basal level ofthe MRP found in these cells.
DISCUSSION
These studies show a modulation of drug transport in human and
murine cells expressing MRP by indomethacin, a non-steroidal
anti-inflammatory drug. Few reports describe compounds that
specifically influence MRP-mediated multidrug resistance. One
study, using the tyrosine kinase inhibitor genistein, demonstrated
the modulation ofdaunorubicin accumulation in human small-cell
lung cancer cells. The high concentration of genistein (200 gM)
prohibited the use of this compound in a cell-proliferation assay
(Versantvoort et al, 1994). Recently, Gekeler et al, have shown that
MRP-associated resistance is efficiently modulated by the bisin-
dolylmaleimide PKC inhibitorGF 109203X andthe LTD4-receptor
antagonist MK571 (Gekeler et al, 1995a,b). In both cases, modula-
tion ofMRP-mediated resistance was shown using the MTT assay.
Depletion of cellular glutathione (GSH) levels with DL-buthio-
nine (S,R)-sulphoximine (BSO), an inhibitor of y-glutamyl
cysteine synthetase, has been shown to modulate MRP-mediated
resistance (Versantvoort et al, 1995; Zaman et al, 1995). The
chemosensitizing effects of BSO are presumed to be due to the
cellular depletion ofGSH. In the vincristine-selected cell lines, we
have demonstrated a reversal of vincristine and etoposide resis-
tance by 25gM BSO (Draper etal, 1996). However, the transport of
some molecules, such as BCECF and calcein, is not affected by
GSH depletion (Draper et al, 1996; Feller et al, 1995). The reason
for the chemosensitization in response to depletion ofintracellular
GSH is unknown. It seems unlikely that the drugs are being trans-
ported as GSH-modified adducts, as no modified drugs can be
detected (Zaman et al, 1995). This leaves open the possibility that
drug transport is directly affected by GSH or that the transport of
GSH or other GSH-modified compounds acts in some manner to
facilitate transport ofthe chemotherapeutic agents.
In this present study, we have used the altered accumulation of
the fluorescent dye BCECF to identify a modulator of multidrug
resistance in MRP-overexpressing cell lines. Indomethacin both
increased the accumulation of BCECF (Figure 1) and vincristine
(Figure 4) and sensitized MRP-overexpressing cells to vincristine
and doxorubicin (Table 1). It appears to have little effect on the
function of P-gp as it failed to modulate P-gp-mediated altered
accumulation of rhodamine (Figure 3) and vincristine (Figure 4)
and failed to alter the drug resistance ofboth human and murine P-
gp-overexpressing cell lines (Table 1). These data suggest that
indomethacin is a specific modulator ofMRP.
Indomethacin is a well-known inhibitor of prostaglandin
synthesis and has also been shown to be a potent inhibitor of
glutathione-S-transferase (Primiano and Novak, 1993). It has
previously been used to enhance the anti-cancer activity of chlo-
rambucil (Hall et al, 1989; Yang et al, 1992) and has also been
shown to give partial reversal ofmethotrexate and cholate efflux in
L1210 cells (Henderson et al, 1994).
The mechanism behind indomethacin's ability to chemosensitize
MRP-overexpressing cells remains unknown at this time. As the
addition of exogenous prostaglandins did not restore MRP func-
tion, it seems unlikely that indomethacin is functioning by
inhibiting prostaglandin synthesis. This is in agreement with
previous studies which looked at the effect ofindomethacin on the
efflux ofBCECF in non-drug-resistant human and canine cell lines
(Collington et al, 1991, 1992). Indomethacin also does not appear
to be functioning by altering cellular GSH content as we could find
no ability of the drug to alter GSH levels. There are two likely
explanations for indomethacin function. First indomethacin could
be interacting directly with MRP, functioning as a competitive
inhibitor. Indomethacin has a pKa of 4.1, so that at physiological
pH the drug would be in an anionic form (Tonnessen et al, 1989).
MRP is known to display preference for more hydrophilic
compounds and has been shown to transport amphiphilic organic
anions (Cole et al, 1994; Leier et al, 1994). Its ability to block
BCECF efflux suggests such an activity. However, as the MRP-
and P-gp-expressing cell lines displayed no difference in the toxi-
city level of indomethacin, it does not seem likely that the drug is
being effluxed; however, indomethacin may be binding to MRP
and inhibiting efflux in another manner. Alternatively indo-
methacin may be functioning by inhibiting the function of GST,
which may, like GSH, be necessary for proper drug efflux.
Indomethacin has been shown to function as an inhibitor ofclass ,
glutathione-S-transferases at a concentration of 1 ,UM (Primiano
and Novak, 1993). Further, in a chlorambucil-resistant cell line
demonstrating a 40-fold increase in an alpha class GST,
indomethacin functioned as a chemosensitizing agent (Hall et al,
1989).
The clinical relevance ofMRP is presently unknown. However,
increases in P-gp and MRP havebeen reported in different types of
leukaemias refractory to chemotherapy (Goasguen et al, 1993;
Zhou et al, 1995). The concentration of indomethacin needed to
increase drug susceptibility is clinically relevant (10 gM) and
indomethacin is known to be well tolerated (Tonnessen et al, 1989;
Statkevich et al, 1993). This suggests that indomethacin may be a
valuable adjunct to chemotherapy to block MRP-mediated resis-
tance as well as, in conjunction with aP-gp modulator, to deal with
cells expressing both efflux proteins.
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